Published: 15 September 2016
Author(s): Andras T. Deak, Katharina Troppan, Alexander R. Rosenkranz
Section: Narrative Review

Anemia is a common complication of cancer and chronic kidney disease (CKD) associated with decreased physical performance as well as poor prognosis for life expectancy. Renal and cancer-induced anemia share common features regarding pathogenesis and therapeutic strategies. It is typically treated with iron substitution, erythropoiesis-stimulating agents (ESA) and in refractory cases with red blood cell transfusions. However, studies of the past few years unveiled numerous setbacks in the use of ESAs.

Newsletters

Stay informed on our latest news!